More Information Coming Soon!

NACLC26 is especially valuable as an opportunity to present your work. Its timing is uniquely positioned between other major conferences, making it an excellent venue to showcase ongoing research and receive meaningful feedback. Stay tuned for details on how to submit across a range of topics and disciplines!

Please review the below frequently asked questions, important dates, and guidelines carefully.

Abstract Submission Opens

Abstract Submission Closes

Abstract Notifications

LBA Submission Closes

LBA Notifications

Poster PDF Submission Deadline

July 31, 2026

September 28, 2026

October 19, 2026

November 5, 2026

November 11, 2026

November 19, 2026

Submission Guidelines
  • Research work should be original and innovative. Work can be presented prior to the IASLC | ASCO 2026 North America Conference on Lung Cancer but MUST include new information/data.
  • Abstracts must not exceed 500 words in length (not including title and authors).
  • The abstract title must not exceed 75 words in length.
  • Tables may be included, and each will count as 100 words.
  • A maximum of two images may be included; each will count as 100 words.
  • Tables, images and graphs must be uploaded in GIF, JPEG, JPG or PNG format at 300 dpi and 100% size. Any higher resolution is acceptable.
  • Abstracts must be structured with the following headings: Background, Methods, Results, Conclusion
  • Enter the authors and affiliations at the top of the abstract.
  • There is no limit to the number of co-authors.
  • There is a limit of one presenting author.
  • The presenting author must register by the date listed below or the abstract will be removed from the program.
  • Once an abstract is submitted it cannot be deleted, modified or corrected in the system. All accepted abstracts will be published exactly as submitted.
  • Any abstracts in “Draft” status after the submission deadline has passed will not be considered for review. It is the abstract submitters’ responsibility to ensure that all abstracts you wish to be reviewed have been properly submitted.
  • To withdraw a submitted abstract, please contact meetings@iaslc.org. Include the abstract number and abstract title in your email.
What types of abstracts can be submitted?
  • Regular Abstract
  • Definition: Original scientific research that summarizes work done and major research findings.
  • Required sections for abstract submission:
  • Introduction
  • Methods
  • Results
  • Conclusions
  • Clinical Trials in Progress
  • Definition: Ongoing trials that have not reached pre-specified endpoints for analysis.
  • Required sections:
  • Introduction
  • Methods
  • Optional sections:
  • Results
  • Conclusion
  • Case Report
  • Definition: Detailed report of symptoms, signs, diagnosis, treatment and follow up of an individual patient. Must include a minimum of three (3), but preferably five (5) cases.
  • Required sections:
  • Introduction including selective literature review
  • Methods
  • Results
  • Conclusion
  • Late-Breaking Abstract
  • Definition:
  • LBA designation will only be given to impactful prospective studies that will change clinical practice within the year and whose data are not available at the time of regular abstract submission due to study events and/or timelines.
  • LBA designation is not a means for extending the regular abstract deadline. Highly impactful studies that have complete data should be submitted as a regular abstract and will be considered for a prominent oral presentation based on scoring by the program committee.
  • For abstracts that do not meet LBA requirements the authors will be given 5 business days to update the submitted data before the abstracts are re-classified as regular abstracts and rated based on the updated information.
  • Submission requirements:
  • Authors of LBA must submit an intent to submit an LBA abstract through the abstract portal by the abstract submission deadline.
  • Required sections for intent to submit an LBA:
  • Explanation of why the abstract qualifies as late-breaking
  • Introduction
  • Methods, including applicable endpoints
  • Types of anticipated analysis and data to be reported
  • LBA Eligibility Review:
  • The Committee will review all submissions with the intent to submit LBA abstracts after the regular abstract submission deadline. Authors of approved LBA applications will be notified and advised on the processes for submitting final data. Authors of abstracts not being accepted for LBA submissions will be notified and given 5 days to submit all available data before the abstract is re-classified as a regular abstract and included in the regular abstract review and scheduling process.
What is the plagiarism policy?

Plagiarism encompasses all of the following:

1. Direct: intentionally submitting another person’s words or ideas verbatim as one’s own;

2. Self-plagiarism: submitting work that has been previously published or presented;

3. Mosaic plagiarism: stringing together portions of text from other sources;

4. Lack of attribution: failing to appropriately identify and cite sources for language or ideas that are incorporated.

For more information see: Das N, Panjabi M. Plagiarism: Why is it such a big issue for medical writers? Perspect Clin Res. 2011;2(2):67–71. doi:10.4103/2229-3485.80370 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121267/

Screening: IASLC screens all abstracts using anti-plagiarism software. Abstracts identified as having high levels of plagiarized content will be evaluated by IASLC staff and appropriate actions taken. Penalties for plagiarism may include: Rejection of abstract, and/or author(s) banned from making presentations at IASLC conferences.

What languages can I use in my abstract?

Abstracts will be accepted in English only.

Is industry allowed to be in a lead or senior author position for abstract submissions?

Yes, industry is permitted to be in the lead or senior author positions in the author list of an abstract.

Are there restrictions towards industry authors presenting abstracts?

Industry/pharmaceutical/commercial authors are permitted to present a poster or e-poster presentations. 

Are there restrictions towards non-IASLC members presenting abstracts?

No, both members and non-members may submit or present abstracts.

Is there a limit to the number of abstracts an author can submit or present?

No, there is no submission limit.

There is no limit to the number of poster abstracts that an author may present however authors are limited to presenting one (1) oral abstract.

Is there a charge for abstract submission?

No.

Are abstracts from the conference published?

All abstracts accepted by the Scientific Program Committee will be published in the Journal of Thoracic Oncology and on the conference website prior to the meeting. It is mandatory to agree to this at the time of submission.

Who holds the copyright of the abstracts or presentation materials?

The authors of the abstract hold the copyright, however, IASLC reserves the right to sell and retain any revenue/income from selling the abstracts, presentation materials or recordings of the presentations.

The authors hold the copyright of presentation materials, however, IASLC reserves the right to publish and sell copies/recordings of the presentation materials.

How do I submit my accepted poster PDF?

Final poster PDFs should be emailed to meetings@iaslc.org and our team will upload to Lung Cancer 360.

Is onsite poster printing available?

No, poster printing services are not coordinated by the IASLC.

When will abstracts be available for viewing?

Abstract titles and PDF copies will be released on the program by November 5, 2026. Embargoed LBA will be released upon presentation at the conference.